Lexicon Pharmaceuticals
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Texas, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
2445 Technology Forest Blvd Fl 11, The W...Phone Number
(281) 863-3000Website
www.lexpharma.comRevenue
$49.8 MillionStock Symbol
LXRXIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
3
5
1
1
1
1
About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals is a biopharmaceutical company that is applying a unique approach to gene science based on Nobel Prize-winning technology to discover and develop precise medicines for people with serious, chronic conditions. Using a patient driven approach, we are working to discover and develop innovative medicines to safely and effectively treat disease and improve patient lives.Explore more
Lexicon Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Lexicon Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Lexicon Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Lexicon Pharmaceuticals is spiking on competitors!
Click to see if Lexicon Pharmaceuticals had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Lexicon Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Lexicon Pharmaceuticals recently announced quarterly report
Product Launch: Get notified when Lexicon Pharmaceuticals launches new products
Congratulate Masked Content for being promoted to Masked Content at Lexicon Pharmaceuticals
Funding: Get notified immidiatlly once Lexicon Pharmaceuticals has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Lexicon Pharmaceuticals
Compare insights from companies similar to Lexicon Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$23.9M
51-200
Private
$126.7M
2001
SB
Sofia BlehautAssociate Director and Regional Clinical Operations Manager
Company Profile Activity
Activity Insights
Lexicon Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Lexicon Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Lexicon Pharmaceuticals.
Lexicon Pharmaceuticals financials insights
Gather financial insights about Lexicon Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2009
Stock Offering
$55.2M
2010
Stock Offering
$181.4M
2012
Stock Offering
$37.2M
2014
Multiple Rounds
$273.7M
2017
Debt
$200M
2022
Debt
$150M
2026
Private Equity
$55.7M
Lexicon Pharmaceuticals Tech Stack
A closer look at the technologies used by Lexicon Pharmaceuticals
See more technologies
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Person-Based
Governmental Affairs & Regulation, Doctors / Physicians, Regulations
Project
Lexicon Pharmaceuticals has reported that hypertrophic cardiomyopathy trial design was informed by its scientific steering committee of experienced academic sites and received guidance and input from the FDA regarding trial design and endpoint adequacy prior to initiation.
Medical Research, Clinical Operations
Project
worked with the FDA over time to establish the Steno trial, a 2,000-patient study with 1,000 patients on enhanced therapy (at least one-third on sotagliflozin) treated for 5 years.
Pharmaceuticals, Clinical Operations
Project
Medical Research, Clinical Operations
Lexicon Pharmaceuticals News & Media
Lexicon Pharmaceuticals vs. Pfizer: Which Drugmaker Stock Is a Better Buy in 2026?
One company posts rapid revenue growth but remains unprofitable, while the other boasts global scale and steady cash flow. See how their fundamentals stack up.Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions
Presentations highlight consistent A1c reductions with sotagliflozin in type 1 diabetes and pharmacokinetics of pilavapadin across renal function groups Presentations highlight consistent A1c reductions with sotagliflozin in type 1 diabetes and pharmacokinetics of pilavapadin across renal function groupsLexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference
THE WOODLANDS, Texas, May 28, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 4, 2026 at 2:00 p.m. ET in New York City.Lexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference
THE WOODLANDS, Texas, May 12, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the 4th Annual H.C. Wainwright BioConnect Investor Conference, taking place at the Nasdaq World Headquarters in New York City, on May 19, 2026.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Lexicon Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Lexicon Pharmaceuticals is a biopharmaceutical company that is applying a unique approach to gene science based on Nobel Prize-winning technology to discover and develop precise medicines for people with serious, chronic conditions. Using a patient driven approach, we are working to discover and develop innovative medicines to safely and effectivel... Read More
